Growth Metrics

CapsoVision (CV) Common Equity (2024 - 2025)

CapsoVision recorded quarterly Common Equity of $13.3 million in Q4 2025, down 35.13% quarter-over-quarter from $20.4 million in Q3 2025, and up 110.24% year-over-year from $6.3 million in Q4 2024.

CapsoVision's Common Equity history runs 2 years deep, the most recent figure standing at $13.3 million for Q4 2025.

  • In Q4 2025, Common Equity rose 110.24% year-over-year to $13.3 million; the TTM figure through Dec 2025 stood at $13.3 million (up 110.24% YoY), while the FY2025 annual figure was $13.3 million, up 110.24% from the prior year.
  • Common Equity came in at $13.3 million for Q4 2025 at CapsoVision, down from $20.4 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $20.4 million in Q3 2025 to a low of -$139.0 million in Q2 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Common Equity (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn 52.70 Bn
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn 22.98 Bn
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn 48.99 Bn
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn 26.10 Bn
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn 10.33 Bn
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn -
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn 2.96 Bn
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn 10.68 Bn
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn 7.20 Bn
10 CapsoVision 167.59 Mn 157.48 Mn 1.95 Mn 13.26 Mn

Historic Data

Download Data 🔒
DateValue
Dec 31, 2025 13.26 Mn
Sep 30, 2025 20.44 Mn
Jun 30, 2025 -138.99 Mn
Dec 31, 2024 -129.51 Mn
Sep 30, 2024 -124.99 Mn
Jun 30, 2024 -119.21 Mn